Table 3.
Laboratory data and miRNA-224 relative expression in the studied groups
| Parameter | HCC (n = 24) | LC (n = 24) | Ctrl (n = 24) | p1 HCC/LC | p2 HCC/Ctrl | p3 LC/Ctrl |
|---|---|---|---|---|---|---|
| ALT (U/l) | 96.4 ±159.1 | 33.7 ±22.9 | 17.0 ±2.6 | 0.031* | 0.009* | 0.001* |
| AST (U/l) | 185.3 ±340.9 | 61.3 ±45.7 | 16.6 ±3.9 | 0.042* | 0.010* | 0.000* |
| Albumin (g/dl) | 2.3 ±0.4 | 2.6 ±0.5 | 4.4 ±0.2 | 0.027* | 0.000* | 0.000* |
| T-Bil (mg/dl) | 7.5 ±7.7 | 5.7 ±8.7 | 0.6 ±0.1 | 0.228 | 0.000* | 0.003* |
| ALP (U/l) | 126.3 ±79.1 | 98.5 ±28.3 | 101.8 ±10.6 | 0.056 | 0.070 | 0.298 |
| GGT (U/l) | 49.0 ±33.1 | 41.5 ±20.8 | 17.4 ±4.2 | 0.178 | 0.000* | 0.000* |
| BUN (mg/dl) | 64.9 ±51.1 | 44.1 ±30.6 | 11.9 ±1.8 | 0.047* | 0.000* | 0.000* |
| Creatinine (mg/dl) | 1.3 ±0.6 | 1.1 ±0.2 | 0.8 ±0.1 | 0.062 | 0.000* | 0.000* |
| INR | 1.6 ±0.3 | 1.4 ±0.6 | 1.0 ±0.0 | 0.192 | 0.000* | 0.000* |
| Hb (g/dl) | 10.1 ±1.9 | 9.1 ±2.0 | 13.4 ±1.0 | 0.034* | 0.000* | 0.000* |
| WBC count (× 103/µl) | 6.9 ±3.0 | 6.7 ±4.1 | 6.3 ±1.4 | 0.433 | 0.177 | 0.302 |
| Platelets count (× 103/µl) | 97.7 ±52.2 | 58.5 ±127.2 | 226.5 ±69.8 | 0.018* | 0.00* | 0.013* |
| AFP (ng/ml) | 253.7 ±223.5 | 39.04 ±30.5 | 5.75 ±2.87 | 0.004* | 0.001* | 0.045* |
| miRNA-224 | 64.7 ±73.1 | 1.3 ±1.3 | 1.1 ±0.4 | 0.001* | 0.001* | 0.297 |
HCC – hepatocellular carcinoma, LC – liver cirrhosis, Ctrl – normal control group, n – number, ALT – alanine aminotransferase, AST – aspartate aminotransferase, T-Bil – total bilirubin, ALP – alkaline phosphatase, GGT – g-glutamyl transpeptidase, BUN – blood urea nitrogen, INR – international normalized ratio, Hb – hemoglobin, WBC – white blood cell, AFP – α-fetoprotein, miRNA-224 – micro-ribonucleic acid 224 (presented as relative expression), p1 – comparison between HCC and LC, p2 – comparison between HCC and normal control group, p3 – comparison between LC and normal control group
*
statistically significant at p < 0.05